Instil Bio, Inc.

NasdaqCM TIL

Instil Bio, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2024: -25.08%

Instil Bio, Inc. Return on Assets (ROA) is -25.08% for the Trailing 12 Months (TTM) ending September 30, 2024. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Instil Bio, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2022 was -39.48%, a -94.31% change year over year.
Instil Bio, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2021 was -20.32%.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

NasdaqCM: TIL

Instil Bio, Inc.

CEO	Mr. Bronson Crouch
IPO Date	March 19, 2021
Location	United States
Headquarters	3963 Maple Avenue
Employees	49
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

Key trends

Past 5 years